CBIO Q2 2021 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$337M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$142

Gross Profit

$142100.0% margin

Operating Income

-$14M-10144001.4% margin

Net Income

-$14M-10140324.6% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$124M

Total Liabilities

$12M

Stockholders' Equity

$112M

Cash & Equivalents

$119M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$142	$0	—
Gross Profit	$142	-$67,681	+100.2%
Operating Income	-$14M	-$14M	-2.1%
Net Income	-$14M	-$14M	-2.3%